Home Cart 0 Sign in  

[ CAS No. 544-63-8 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 544-63-8
Chemical Structure| 544-63-8
Structure of 544-63-8 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 544-63-8 ]

Related Doc. of [ 544-63-8 ]

Alternatived Products of [ 544-63-8 ]

Product Details of [ 544-63-8 ]

CAS No. :544-63-8 MDL No. :MFCD00002744
Formula : C14H28O2 Boiling Point : -
Linear Structure Formula :- InChI Key :TUNFSRHWOTWDNC-UHFFFAOYSA-N
M.W : 228.37 Pubchem ID :11005
Synonyms :
Tetradecanoic acid;C14:0 Fatty acid;n-Tetradecan-1-oic acid;n-Tetradecanoic acid;544-63-8
Chemical Name :Tetradecanoic acid

Calculated chemistry of [ 544-63-8 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.93
Num. rotatable bonds : 12
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 71.18
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -3.35 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.32
Log Po/w (XLOGP3) : 6.11
Log Po/w (WLOGP) : 4.77
Log Po/w (MLOGP) : 3.69
Log Po/w (SILICOS-IT) : 4.37
Consensus Log Po/w : 4.45

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 1.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.85

Water Solubility

Log S (ESOL) : -4.31
Solubility : 0.0111 mg/ml ; 0.0000486 mol/l
Class : Moderately soluble
Log S (Ali) : -6.67
Solubility : 0.0000483 mg/ml ; 0.000000211 mol/l
Class : Poorly soluble
Log S (SILICOS-IT) : -4.51
Solubility : 0.00712 mg/ml ; 0.0000312 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 3.0
Synthetic accessibility : 2.09

Safety of [ 544-63-8 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P264-P280-P305+P351+P338-P337+P313-P403-P501 UN#:N/A
Hazard Statements:H319 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 544-63-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 544-63-8 ]
  • Downstream synthetic route of [ 544-63-8 ]

[ 544-63-8 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 6066-82-6 ]
  • [ 544-63-8 ]
  • [ 69888-86-4 ]
YieldReaction ConditionsOperation in experiment
72%
Stage #1: With dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃; for 0.166667 h;
Stage #2: at 20℃; for 22.5 h;
Tetradecanoic acid [3.00 g (13.1 mmol)] and 3.24 g of N,N′-dicyclohexylcarbodiimide (15.7 mmol) were dissolved in 26.2 ml of dry tetrahydrofuran and stirred at room temperature for 10 min. Then, 1.81 (15.7 mmol) of N-hydroxysuccinimide in 14.1 ml of the same solvent were added and the reaction mixture was stirred at room temperature for 22.5 h. TLC analysis [CHCl3/MeOH (50:1, v/v)] revealed a complete conversion of the educt. After this, the reaction mixture was filtrated by suction. The solvent was removed under reduced pressure and the residue was recrystallized from ethanol containing a trace of H2O (34). The product was obtained as a colorless solid (3.08 g, 72percent), 1H-NMR (300 MHz,CDCl3): [ppm] = 2.83 (s, 4H, H-3, 4), 2.60 (t, 2H,3 J H2 ′ -H3 ′ = 7.5 Hz, H-2 ′ ), 1.74 (tt, 2H, 3 J H3′-H4′ = 7.5 Hz, 3 JH3′-H2′ = 7.5Hz, H-3 ′ ), 1.46-1.18 (m, 20H), 0.88 (t, 3H, 3 J H14 ′ -H13 ′ = 6.7 Hz,H-14 ′ ), 13 C-NMR (75 MHz, CDCl3): [ppm] = 169.15 (R C ON,C-2, 5), 168.68 (R C O 2 R ′ , C-1 ′ ), 31.90 (CH 2 , C-2 ′ ), 30.93 (CH 2 ,C-12 ′ ), 29.63-28.77 (8 CH 2 ), 25.57 (CH 2 , C-3, 4), 24.56 (CH 2 ,C-3 ′ ), 22.67 (CH 2 , C-13 ′ ), 14.09 (CH 3 , C-14 ′ ), EI-MS: m/z 211.3[M+-C4H4NO3], 129.1 [C8H17O+ ], 98.2 [C7H14 ], 84.1 [C6H12 ], CHN analysis: calc.: C, 66.43; H, 9.60; N, 4.30, found: C, 66.03; H,9.63; N, 4.29.
67% With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane Myristic acid (1.5 g, 6.6 mmol) was dissolved in dichloromethane (30 ml) and the mixture was stirred. To this solution were added N-hydroxysuccinimide (0.91 g, 1.2 eq.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (1.5 g, 1.2 eq.), and the mixture was stirred overnight. After washing twice with water, the mixture was washed once with saturated brine, dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate/hexane=1/3) to give the object product (1.4 g, yield 67percent). The NMR measurement results of the obtained myristic acid-N-hydroxysuccinimide ester (C14-NHS) are shown below. Myristic Acid-N-Hydroxysuccinimide Ester (C14-NHS) (0195) 1H-NMR (CDCl3) δ: 2.83 (4H, s), 2.60 (2H, t, J=7.6 Hz), 1.74 (2H, q, J=7.6 Hz), 1.44 (2H, q, J=6.9 Hz), 1.48-1.22 (18H, m), 0.88 (3H, t, J=6.8 Hz).
Reference: [1] RSC Advances, 2015, vol. 5, # 81, p. 66339 - 66354
[2] Journal of Pharmaceutical Sciences, 1994, vol. 83, # 2, p. 233 - 238
[3] Journal of Pharmacology and Experimental Therapeutics, 2004, vol. 309, # 1, p. 340 - 347
[4] Angewandte Chemie, 1996, vol. 108, # 15, p. 1791 - 1794
[5] Journal of Mass Spectrometry, 1995, vol. 30, # 6, p. 900 - 910
[6] Journal of Lipid Research, 2014, vol. 55, # 12, p. 2692 - 2704
[7] Patent: US9663784, 2017, B2, . Location in patent: Page/Page column 41
[8] Agricultural and Biological Chemistry, 1982, vol. 46, # 2, p. 597 - 600
[9] Tetrahedron, 1991, vol. 47, # 39, p. 8407 - 8416
[10] Agricultural and Biological Chemistry, 1986, vol. 50, # 10, p. 2561 - 2572
[11] Journal of Medicinal Chemistry, 2001, vol. 44, # 13, p. 2188 - 2203
[12] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 10, p. 3117 - 3121
[13] Organic and Biomolecular Chemistry, 2011, vol. 9, # 3, p. 820 - 833
[14] Organic and Biomolecular Chemistry, 2012, vol. 10, # 30, p. 6121 - 6129
[15] Chemistry Letters, 2013, vol. 42, # 2, p. 127 - 129
[16] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 6, p. 1763 - 1767
[17] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 4, p. 476 - 480
[18] RSC Advances, 2016, vol. 6, # 30, p. 24808 - 24819
[19] Patent: CN105461681, 2016, A, . Location in patent: Paragraph 0024; 0025
[20] Patent: US2018/222960, 2018, A1, . Location in patent: Paragraph 0395-0396
  • 2
  • [ 123-56-8 ]
  • [ 544-63-8 ]
  • [ 69888-86-4 ]
Reference: [1] Journal of Controlled Release, 2010, vol. 144, # 1, p. 55 - 64
  • 3
  • [ 544-63-8 ]
  • [ 69888-86-4 ]
Reference: [1] Bioconjugate Chemistry, 2017, vol. 28, # 11, p. 2772 - 2783
  • 4
  • [ 64-17-5 ]
  • [ 544-63-8 ]
  • [ 124-06-1 ]
YieldReaction ConditionsOperation in experiment
98.43% for 4.5 h; Sonication Myristic acid (12 g, 53 mmol) was esteried by using a 4percent wt sulfuric acid solution in ethanol (50 mL) and the mixture was sonicated for 4.5 h with a Branson 1210 ultrasonic cleaner (Branson, Danbury, CT, USA). After the reaction, the solvent was evaporated. The ltrate was diluted with ethyl acetate (40 mL) and washed with 5percent wt sodium hydroxide solution until neutral. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated to obtain 13.25 g of ethyl myristate as a yellowish liquid (98.43percent yield). FT-IR (cm−1): 2924 (C-H stretching), 1735 (C=O ester), 1458 (CH2 bending), 1180 (C-O ester). GC: 98.90percent ethyl myristate (retention time (tR) = 34.4 min, [M−15]+ = 256).
93% With cerium(III) trislaurylsulfonate monohydrate In neat (no solvent) at 80℃; for 6 h; General procedure: Carboxylic acid (1 mmol), alcohol (6 mmol) and 5 molpercent catalyst were added to a 10 ml round-bottom flask with a reflux condenser.The reaction mixture was continuously stirred using a magnetic stirrer (800 rpm) at 80 °C in an oil-bath for an appropriate time, andthe progress of reaction was monitored by TLC. At the end of reac-tion, the mixture was cooled to room temperature and poured intowater. Afterwards, the filtered cake was purified by chromatography on silica gel using petroleum ether/ethyl acetate (20:1) aseluent to give the pure product.
94 %Chromat. for 4 h; Reflux General procedure: General procedure for the synthesis of compounds (6a-p); organic acid (0.40 mmol.), and catalyst (0.0005 mmol.) was combined with 20 mL ethanol in a 50 mL round bottomed flask equipped with a stir bar. Reaction was allowed to stir at reflux temperature for the appropriate amount of time (4 h). After completion of reaction, the reaction mixture was concentrated in vacuum to give a crude product which was analyzed by 1H NMR and GC-MS.
Reference: [1] Molecules, 2018, vol. 23, # 12,
[2] Journal of Organic Chemistry, 1996, vol. 61, # 6, p. 1962 - 1974
[3] Journal of Molecular Catalysis A: Chemical, 2014, vol. 392, p. 76 - 82
[4] Tetrahedron Asymmetry, 2010, vol. 21, # 8, p. 952 - 956
[5] Catalysis Today, 2015, vol. 255, p. 27 - 32
[6] New Journal of Chemistry, 2018, vol. 42, # 15, p. 12745 - 12753
[7] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 11, p. 3023 - 3029
[8] Ultrasonics Sonochemistry, 2012, vol. 19, # 3, p. 387 - 389
[9] Bulletin of the Chemical Society of Japan, 1989, vol. 62, # 7, p. 2353 - 2361
[10] Journal of the American Chemical Society, 1933, vol. 55, p. 3827
[11] Justus Liebigs Annalen der Chemie, 1841, vol. 37, p. 155
[12] Catalysis Letters, 2010, vol. 135, # 3-4, p. 207 - 211
[13] European Journal of Medicinal Chemistry, 2010, vol. 45, # 7, p. 2806 - 2816
[14] Biocatalysis and Biotransformation, 2011, vol. 29, # 4, p. 113 - 118
[15] Chinese Chemical Letters, 2011, vol. 22, # 11, p. 1293 - 1296
[16] Medicinal Chemistry Research, 2012, vol. 21, # 3, p. 382 - 394
[17] Tetrahedron Letters, 2012, vol. 53, # 13, p. 1630 - 1633
[18] Catalysis Letters, 2013, vol. 143, # 11, p. 1240 - 1246
[19] RSC Advances, 2016, vol. 6, # 29, p. 24285 - 24289
  • 5
  • [ 544-63-8 ]
  • [ 2034-56-2 ]
  • [ 17278-74-9 ]
  • [ 17278-73-8 ]
  • [ 82177-86-4 ]
Reference: [1] Advanced Synthesis and Catalysis, 2005, vol. 347, # 7-8, p. 1090 - 1098
  • 6
  • [ 544-63-8 ]
  • [ 16899-08-4 ]
  • [ 17278-74-9 ]
Reference: [1] Angewandte Chemie - International Edition, 2003, vol. 42, # 28, p. 3299 - 3301
[2] Angewandte Chemie - International Edition, 2003, vol. 42, # 28, p. 3299 - 3301
  • 7
  • [ 36653-82-4 ]
  • [ 544-63-8 ]
  • [ 57-10-3 ]
  • [ 2599-01-1 ]
  • [ 540-10-3 ]
Reference: [1] Patent: US2005/33070, 2005, A1, . Location in patent: Page/Page column 1
[2] Patent: US2005/33070, 2005, A1, . Location in patent: Page/Page column 1-2
[3] Patent: US2005/33070, 2005, A1, . Location in patent: Page/Page column 2
[4] Patent: US2005/33070, 2005, A1, . Location in patent: Page/Page column 2
[5] Patent: US2005/33070, 2005, A1, . Location in patent: Page/Page column 2
  • 8
  • [ 74420-88-5 ]
  • [ 5041-09-8 ]
  • [ 544-63-8 ]
Reference: [1] Chemical & Pharmaceutical Bulletin, 1981, vol. 29, # 6, p. 1791 - 1793
Same Skeleton Products
Historical Records

Similar Product of
[ 544-63-8 ]

Chemical Structure| 287111-05-1

A1267957[ 287111-05-1 ]

Myristic Acid-13C14

Reason: Stable Isotope

Chemical Structure| 62217-70-3

A1268089[ 62217-70-3 ]

Myristic acid-14-13C

Reason: Stable Isotope

Chemical Structure| 287111-20-0

A1268087[ 287111-20-0 ]

Myristic acid-1,2-13C2

Reason: Stable Isotope

Chemical Structure| 57677-52-8

A189709[ 57677-52-8 ]

Tetradecanoic-1-13C acid

Reason: Stable Isotope